Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 9044 results

  1. Baloxavir marboxil granules for treating and preventing influenza in people 3 weeks and over [TSID12432]

    Awaiting development Reference number: GID-TA12479 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]

    Awaiting development Reference number: GID-TA12478 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Islatravir–lenacapavir for treating HIV-1 in people with virological suppression on standard HIV-1 treatment [TSID12428]

    Awaiting development Reference number: GID-TA12475 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Zibotentan–dapagliflozin for treating chronic kidney disease with proteinuria [TSID12423]

    Awaiting development Reference number: GID-TA12474 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Datopotamab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after osimertinib [TSID12418]

    Awaiting development Reference number: GID-TA12469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    Awaiting development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Alectinib for treating unresectable locally advanced non-small-cell lung cancer [GID-TA12468]

    Awaiting development Reference number: GID-TA12468 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-HTG10869 Expected publication date:  19 November 2026

    HealthTech guidance
    In development

  12. Unilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor

    In development Reference number: GID-HTG10859 Expected publication date:  17 December 2026

    HealthTech guidance
    In development

  13. Excimer Laser Trabeculotomy (ELT) for glaucoma

    Awaiting development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. Miniature lens system implantation for advanced age-related macular degeneration

    Awaiting development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  15. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTG10173 Expected publication date: TBC

    HealthTech guidance
    Awaiting development